N. Yuksel et al., The short-term effect of adding brimonidine 0.2% to timolol treatment in patients with open-angle glaucoma, OPHTHALMOLA, 213(4), 1999, pp. 228-233
Brimonidine, a highly selective alpha(2)-adrenoceptor agonist was studied t
o determine its ocular hypotensive effect and side effects in patients with
elevated intraocular pressure (IOP) while on continuing therapy with timol
ol. This was a prospective, randomized, placebo-controlled study in 15 pati
ents with primary open-angle or pseudoexfoliation glaucoma on therapy recei
ving timolol 0.5% twice daily, with IOP greater than or equal to 22 mm Hg i
n one eye. IOP measurements, blood pressure and pulse rate were assessed on
2 days at a baseline and 1, 2, 4, 6 and 8 h later. A single drop of brimon
idine 0.2% or placebo was added to treatment with timolol. The reductions i
n IOP at all time intervals observed with brimonidine + timolol were signif
icantly greater than those with timolol + placebo. The maximum mean net dec
rease in IOP was 19.23 +/- 10.60% at 4 h. Statistically significant decreas
es in systemic blood pressure and pulse rate without clinical symptoms were
observed in the group receiving brimonidine + timolol. This study suggests
that a combination of brimonidine and timolol may have potential in the tr
eatment of glaucoma. Further clinical trials with brimonidine are indicated
to assess its further role as adjunctive agent.